Danaher Corporation (NYSE:DHR) is one of the best medical stocks to invest in according to billionaires. RBC Capital resumed coverage of Danaher Corporation (NYSE:DHR) with an Outperform rating on May 14, setting a price target of $200. The firm told investors in a research note that it sees the company’s growth recovering with an improvement in the bioprocess market. It further added that factors like the lapping of “idiosyncratic headwinds”, a sustained bioprocess rebound, and end market improvement put the company’s 6% revenue growth target within reach for 2027.
For reference, in its financial results for fiscal Q1 2026, Danaher Corporation (NYSE:DHR) reported net earnings of $1.0 billion, or $1.45 per diluted common share. Revenues for the quarter rose 3.5% year-over-year to $6.0 billion, while non-GAAP core revenue grew 0.5% year-over-year. The company also reported that operating cash flow was $1.3 billion, while non-GAAP free cash flow was $1.1 billion.
Danaher Corporation (NYSE:DHR) designs, manufactures, and markets professional, medical, industrial, and commercial products and services, making it a significant diagnostics stock. It operates through Diagnostics, Biotechnology, Life Sciences, and Environmental and Applied Solutions.
While we acknowledge the potential of DHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey on Google News.